Gene content    
RAF1 ( by HUGO)
V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1
Oncogene
V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1
Proto-Oncogene C-RAF
Raf-1
EC 2.7.11.1
CRAF
NS5
c-Raf
Oncogene RAF1
Raf Proto-Oncogene Serine/Threonine Protein Kinase
RAF Proto-Oncogene Serine/Threonine-Protein Kinase
RAF
cRaf
EC 2.7.11
NCBI: 3p25    Ensembl: 3p25.2
RAF1_HUMANSize: 648 amino acidsMass: 73052 Da

  • Subunit: Monomer. Homodimer. Heterodimerizes with BRAF and this heterodimer possesses a highly increased kinase activity compared to the respective homodimers or monomers. Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 activation can induce a negative feedback that promotes the dissociation of the heterodimer. Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2 and protein phosphatase 1 (PPP1CA, PPP1CB and PPP1CC). Interacts with Ras proteins; the interaction is antagonized by RIN1. Weakly interacts with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the interaction mediates the formation of a ternary complex with BRAF, a ternary complex inhibited by GNAI1 (By similarity). Interacts with STK3/MST2; the interaction inhibits its pro-apoptotic activity. Interacts (when phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232'). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2 (By similarity). Interacts with MAP3K5/ASF1 (via N-terminus) and this interaction inhibits the proapoptotic function of MAP3K5/ASK1. Interacts with PAK1 (via kinase domain). The phosphorylated form interacts with PIN1. The Ser-338 and Ser-339 phosphorylated form (by PAK1) interacts with BCL2. Interacts with PEBP1/RKIP and this interaction is enhanced if RAF1 is phosphorylated on residues Ser-338, Ser-339, Tyr-340 and Tyr-341. Interacts with ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, ROCK2, PPP1R12A, PKB/AKT1, PPP2CA, PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and PHB/prohibitin. In its active form, interacts with PRMT5 Selected PDB 3D structures from [IMAGE] and Proteopedia [IMAGE] for RAF1 (see all 19): 1C1Y (3D) [IMAGE] 1FAQ (3D) [IMAGE] 1FAR (3D) [IMAGE] 1GUA (3D) [IMAGE] 1RFA (3D) [IMAGE] 3CU8 (3D) [IMAGE]
  • Tissue specificity: In skeletal muscle, isoform 1 is more abundant than isoform 2 [IMAGE] Pathway & Disease-focused RT2 Profiler PCR Arrays including RAF1 (see all 12): Oncogenes & Tumor Suppressor Genes in human mouse rat Insulin Signaling Pathway in human mouse rat Multipl
  • Function:
    Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation
                          
    Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation
  • Catalytic activity:
    ATP + a protein = ADP + a phosphoprotein
  • Similarity:
    Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily
                          
    Contains 1 phorbol-ester/DAG-type zinc finger
                          
    Contains 1 protein kinase domain
                          
    Contains 1 RBD (Ras-binding) domain [IMAGE]
  • Protein Domain/Family    
    Source ID Domain Name Type
    InterProIPR000719Prot_kinase_domProtein kinaseDomain
    IPR001245Ser-Thr/Tyr_kinase_cat_domTyrosine protein kinaseDomain
    IPR002219Prot_Kinase_C-like_PE/DAG-bdProtein kinase C, phorbol ester/diacylglycerol bindingDomain
    IPR003116Raf-like_ras-bdRaf-like Ras-bindingDomain
    IPR008271Ser/Thr_kinase_ASSerine/threonine protein kinase, active siteActive Sites
    IPR011009Kinase-like_domProtein kinase-likeDomain
    BlocksIPB002219Protein kinase CProtein kinase C, phorbol ester/diacylglycerol binding
    IPB003116Raf-like Ras-bindingRaf-like Ras-binding

    Gene Ontology    
    Type Term Evidence Source Pub
    Biological Process activation of adenylate cyclase activity NAS GOA 15385642
    apoptotic process TAS GOA 8929532
    cell proliferation TAS GOA 8063729
    negative regulation of apoptotic process IDA GOA 19667065
    negative regulation of cell proliferation IDA GOA 9765203
    negative regulation of protein complex assembly IDA GOA 19667065
    positive regulation of peptidyl-serine phosphorylation IDA GOA 19667065
    regulation of Rho protein signal transduction TAS GOA 16649144
    signal transduction TAS GOA 8063729
    wound healing TAS GOA 15943972
    Cellular Component colocalizes_with plasma membrane IDA GOA 16009725
    cytoplasm IDA GOA 17724343
    cytosol IDA GOA 16009725
    Golgi apparatus IPI GOA 17724343
    mitochondrial outer membrane TAS GOA 8929532
    plasma membrane IDA GOA 17724343
    Molecular Function identical protein binding IPI GOA 17979178
    NOT small GTPase binding IPI GOA 12194967
    protein binding IPI GOA 10433554
    protein kinase activity TAS GOA 8063729
    protein serine/threonine kinase activity IDA GOA 19667065

    Disorder & Mutation    
    Source Disease
    SWISS-PROTLEOPARD syndrome 2 (LEOPARD2) [MIM:611554]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. Note=The disease is caused by mutations affecting the gene represented in this entry
    SWISS-PROTNoonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Note=The disease is caused by mutations affecting the gene represented in this entry

    RAF1 cross reference    
    PubMed OMIM Entrez Gene NCKU SNP Nucleotide UniProt Genome Data Viewer HomoloGene